Using miRNA and nanotechnology to develop new treatments for lymphangioleiomyomatosis
Official title: miRNA-Nanotechnology as a novel regenerative therapy for lymphangioleiomyomatosis
Funded at Biosputnik LLC · NIH-10761353 · Data updated 2026-11-12
This study is exploring a new treatment for lymphangioleiomyomatosis (LAM), a rare lung disease mostly affecting women, by using a special therapy that helps improve lung function and recovery while aiming to have fewer side effects than the current medication.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biosputnik LLC NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 25, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $301,016 |
| NIH project number | 1R41HG013603-01A1 |
| Project ID | NIH-10761353 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with lymphangioleiomyomatosis who are seeking alternative treatment options.
✕Less likely to help
Patients with other lung diseases or those who do not have lymphangioleiomyomatosis may not benefit from this research.
What this research studies
This research investigates a novel therapy for lymphangioleiomyomatosis (LAM), a rare lung disease primarily affecting women. The approach involves using miRNA302b mimics delivered through nanotechnology to improve lung function and promote recovery in patients. By targeting the underlying genetic mutations that lead to LAM, the research aims to provide a safer alternative to the current standard treatment, sirolimus, which has significant side effects. The study utilizes a murine model to assess the effectiveness of this new treatment strategy.
Why it matters
Potential benefit: If successful, this research could lead to a safer and more effective treatment option for patients with lymphangioleiomyomatosis.
How similar studies have gone: While the use of miRNA in treatment is a growing field, this specific approach for lymphangioleiomyomatosis is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Biosputnik LLC
New York, United States Active
Researchers
- Principal investigator: Pleimes, Dirk — Biosputnik LLC
- Study coordinator: Pleimes, Dirk
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.